US EditionPublished • loading... • Updated
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
- Formosa Pharmaceuticals has signed an exclusive licensing agreement with Arrotex Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension in Australia and New Zealand.
- Arrotex Pharmaceuticals supplies 50% of Australia's ophthalmology market volume and is a leading company in the field.
- The licensing agreement includes upfront payments, regulatory and sales milestones, and royalties during its term.
- Clobetasol propionate, formulated using Formosa's APNT® nanoparticle platform, was FDA approved in 2024 for twice-daily dosing over 14 days to relieve inflammation and pain.
Insights by Ground AI
31 Articles
31 Articles
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Feb. 23, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), an innovative topical eyedrop for the treatment of inflammation and pain following ocular surgery in Austra…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources31
Leaning Left6Leaning Right4Center9Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 32%
C 47%
R 21%
Factuality
To view factuality data please Upgrade to Premium
